✨ Health Notices




12 SEPTEMBER

NEW ZEALAND GAZETTE

3627

This designation is subject to the following conditions:

  1. The auditing agency must ensure that where it audits
    the provision of health care services for people with
    mental illnesses, a past or present consumer of mental
    health services must fully participate in all aspects
    of the audit.

  2. The auditing agency must inform the Ministry of
    Health immediately by way of written notice if
    there is any change to their accreditation status with
    JAS-ANZ.

This designation will expire three years after the date of this
notification in the New Zealand Gazette.

Dated at Wellington this 6th day of September 2002.

KAREN O. POUTASI, Director-General of Health.

go6148


Medicines Act 1981

Consent to the Distribution of a New Related Product

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the new related product set out in the Schedule hereto:

Schedule

Product:
Macleans Protect Coolmint

Active Ingredient:
Sodium fluoride 0.221%w/w

Dosage Form:
Toothpaste

New Zealand Sponsor:
SmithKline Beecham (NZ) Limited

Manufacturer:
GlaxoSmithKline Australia Pty Limited, Ermington, New South Wales, Australia

Dated this 9th day of September 2002.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go6214


Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set
out in the Schedule hereto:

Schedule

Product:
Zorac

Active Ingredient:
Tazarotene 0.5mg/g

Dosage Form:
Topical gel

New Zealand Sponsor:
Allergan New Zealand Limited

Manufacturer:
Allergan Inc., Waco, Texas, United States of America

Product:
Zorac

Active Ingredient:
Tazarotene 1mg/g

Dosage Form:
Topical gel

New Zealand Sponsor:
Allergan New Zealand Limited

Manufacturer:
Allergan Inc., Waco, Texas, United States of America

Dated this 9th day of September 2002.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go6215


Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or
use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product:
AHF (High Purity) Dried Factor VIII Fraction

Active Ingredient:
Factor VIII, human 250IU

Dosage Form:
Powder for injection

New Zealand Sponsor:
CSL (New Zealand) Limited

Manufacturer:
CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia

Note: This consent is valid for two years from 25 February 2003.

Dated this 9th day of September 2002.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go6216



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2002, No 135


Gazette.govt.nz PDF NZ Gazette 2002, No 135





✨ LLM interpretation of page content

πŸ₯ Designation of Auditing Agency for Health Care Services (continued from previous page)

πŸ₯ Health & Social Welfare
6 September 2002
Health and Disability Services, Auditing Agency, Verification New Zealand Limited
  • KAREN O. POUTASI, Director-General of Health

πŸ₯ Consent to Distribution of New Related Product

πŸ₯ Health & Social Welfare
9 September 2002
Medicines, Toothpaste, Macleans Protect Coolmint, Sodium fluoride
  • G. R. BOYD, Chief Advisor, Safety and Regulation

πŸ₯ Consent to Distribution of Changed Medicine

πŸ₯ Health & Social Welfare
9 September 2002
Medicines, Zorac, Tazarotene, Topical gel
  • G. R. BOYD, Chief Advisor, Safety and Regulation

πŸ₯ Renewal of Provisional Consent to Distribution of New Medicine

πŸ₯ Health & Social Welfare
9 September 2002
Medicines, AHF (High Purity) Dried Factor VIII Fraction, Factor VIII, Powder for injection
  • G. R. BOYD, Chief Advisor, Safety and Regulation